Vastuullisuus, hyvinvointi, immateriaalioikeudet

D&I webinar series

Webinar
keskiviikko 8.9.2021
klo 9.00 – 10.00
Tiedustelut:
[email protected]

D&I Innovation Powerhouse webinar:

Vastuullisuus, hyvinvointi, immateriaalioikeudet

D&I Innovation Powerhouse -webinaarisarjan syyskausi käynnistyy mielenkiintoisella keskustelulla immateriaalioikeuksista. D&I:n tuore osakas Juli Mansnérus puhuu siitä, miten vastuullisuus ja hyvinvointi liittyvät immateriaalioikeuksiin ja mitä vastuullisuusnäkökulmia erityisesti tekoälyyn liittyy. Tämä kiinnostava kehitys näkyy jo erilaisina kaupallisina hankkeina. Osakkaamme Jukka Lång tarjoilee samassa yhteydessä rautaisannoksen siitä, mistä EU:n tekoälyn sääntelyhankkeessa on kysymys.

Johdannoksi webinaarin teemoihin voit katsoa osakkaamme Anna Haapasen keväällä taltioidun haastattelun Business of Digital & Nordic IoT 2021 -tapahtumassa:”What does sustainability have to do with technology law, including IP?” Annaa haastatteli toimittaja Peter Nyman.

Jos et ole saanut kutsua tilaisuuteen ja haluaisit osallistua, voit olla yhteydessä:
[email protected]
Tilaisuutemme ovat ensisijaisesti tarkoitettu asiakkaillemme ja muille sidosryhmillemme.

 

In D&I Innovation Powerhouse’s webinar series our lawyers address topical issues such as cooperation with authorities, legislation of AI-technologies and development, regulation, data transfers and reporting to the company executives.

More by the same author

Welcoming the new year – and a new mechanism for EU-U.S. data transfers?

In October 2022, President Joe Biden’s administration published an executive order regarding a new EU-U.S. Data Privacy Framework, i.e. the replacement of the so-called Privacy Shield mechanism previously allowing transfers of personal data from the EU to the U.S. The executive order immediately sparked the European Commission’s process to assess the new U.S. regime and prepare a respective adequacy decision, which would bring considerable certainty and clarity to trans-Atlantic data flows. In essence, it was a beacon of hope for European organisations having struggled with U.S. data transfers, for example in connection with various established cloud services, ever since the prior Privacy Shield mechanism was invalidated by the Schrems II judgement in July 2020.

The European pharmaceuticals legislation in transition – Finnish perspectives

As part of the EU’s aim to create a stronger European Health Union, the European Commission (“Commission”) published a Pharmaceutical Strategy for the EU (“Strategy”) in November 2020. More recently, the COVID-19 pandemic has highlighted several shortcomings in the EU’s current pharmaceutical system and showed the vulnerability of global supply chains. The Commission now plans to review and revise the EU’s general legislation on medicines for human use to ensure “a future-proof and crisis-resistant medicines regulatory system”. Simultaneously, the Member States of the EU, such as Finland, are dealing with some severe challenges with the economic sustainability of their healthcare systems. We are now facing a true challenge – how to boost the pharmaceutical sector’s global competitiveness and create a regulatory environment, which is attractive for innovation and investment in an economically sustainable way?

Successor framework for Privacy Shield has been revealed bringing long-awaited hope for EU-U.S. data transfers

On Friday 7 October, President Joe Biden’s administration published an executive order regarding a new EU-U.S. Data Privacy Framework, i.e. the replacement of the so-called Privacy Shield mechanism previously allowing transfers of personal data from the EU to the U.S. Although the executive order, in itself, does not legitimise trans-Atlantic data flows, it is a beacon of hope for European organisations having struggled with U.S. data transfers since the Schrems II judgement in July 2020.

Latest insights

Busy times ahead – Review of Finnish merger control in 2022

Alert / 24 Jan 2023
Reading time 6 minutes

D&I Transaction Powerhouse Deal Announcement

Alert / 19 Jan 2023
Reading time 2 minutes